Vinblastine (Sulphate)

Drug #753

Vinblastine is an antineoplastic (anticancer) agent. Vinblastine (Sulphate) is alkaloid derivative of Vinca rosea, the periwinkle plant. Vinblastine (Sulphate) is a parenteral, cell cycle-phase specific antineoplastic agent used in the management of breast carcinoma, bladder carcinoma, Hodgkin's disease, melanoma, and testicular carcinoma. Vinblastine is similar to vincristine in action, but their toxicities differ significantly. Vinblastine was approved by the FDA in 1961. Vinblastine (Sulphate) is used in combination of different anticancer drugs to obtain best therapeutic effect and to minimize side effects or toxicity.

← Previous drug Next drug →

Primary Characteristics

It is of Natural origin and belongs to Alkaloid.

It is classified in Antineoplastic Agent, Plant Derivative pharmacological group. It is also classified under Mitotic Inhibitors .

Molecular Weight: 909.1 · pK_a: 5.4, 7.4 · Solubility in Water: 1 in 10 · Solubility in Alcohol: 1 in 1200 · Non-proprietary name: Vinblastine (Sulphate).

Molecular structure of Vinblastine (Sulphate)

Pharmacokinetics

Absorption: Vinblastine (Sulphate) has an oral bioavailability is 15.5% (±4.5%), pre-systemic (first-pass) metabolism accounts for 0.5% (±0.5%).

Distribution: Vinblastine (Sulphate) has a volume of distribution is 8 - 27 l/kg. plasma protein binding is 99 %.

Elimination: plasma half-life is 20 hr, renal excretion is < 14 %.

Indications

Vinblastine (Sulphate) is primarily indicated in conditions like Acute leukemia, Histiocytosis, Hodgkin's disease, Kaposis sarcoma, Lymphomas, Non-hodgkin's lymphoma, NSAID-associated ulceration, Solid tumor, Testicular cancer.

Contraindications

None recorded.

Dosage

Vinblastine (Sulphate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
100 ug/ sq.meter	100 ug/ sq.meter	—	IV	Once in a Week
Paediatric Dosage (20kg)
4.25 mg/sq.meter	4.25 mg/sq.meter	—	Intra Venous	Once every 1-2 weeks for 3-6 Weeks
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown3 interactions

2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Vinblastine (Sulphate) in overdosage may give rise to further complications which include GI symptoms.

Vinblastine (Sulphate) produces potentially life-threatening effects which include Myelosuppression . Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Vinblastine (Sulphate) are Myelosuppression , Neurotoxicity.

Vinblastine (Sulphate) is known to cause more or less tolerable side effects which are usually transient. These include Abdominal cramps, Constipation , Diarrhea, Paralytic ileus, Vomiting .

Warnings / Precautions

Vinblastin can lower body's ability to fight an infection, consult the doctor if any signs of an infection such as fever, sore throat, rash or chills appear. Avoid contact with people with the flu. Do not have immunizations or vaccinations without consent of doctor and avoid contact with people who have recently received oral polio vaccine. Contraceptive (birth control) measures are recommended for use in men and women while taking this medication. It is not recommended for use in pregnant or nursing women. Avoid aspirin, alcohol and citrus juices.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

10 mg

Storage Conditions

Vinblastine (Sulphate) should be stored Inj (reconstituted soln).

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs

Manufacturers

Manufacturers of Vinblastine (Sulphate) in Pakistan:

Al-Habib Pharmedic